Abacus Health Products (CSE:ABCS,OTCQX:ABAHF) announced that Bed Bath & Beyond (NASDAQ:BBBY) is expanding its distribution of Abacus’ cannabidiol (CBD)-based products from approximately 200 stores to over 1,000 locations across the US.

As quoted in the press release:


Bed Bath & Beyond will be offering 12 unique CBDMEDIC SKUs in its stores covering Pain Relief, First Aid (Eczema and Itch & Rash), Foot & Ankle Pain and Skincare (Acne) categories. In addition to the on-shelf placement the products will also be displayed on off-shelf displays utilizing a specially designed 24-unit point-of-sale display including three top-selling CBDMEDIC SKUs: Arthritis Deep Rub Ointment, Back & Neck Ointment and Muscle & Joint Medicated Pain Relief Spray. The off-shelf displays are being rolled out to 780 stores.

With the addition of these locations the CBDMEDIC line of products will be available in over 7,800 retail locations across the United States.

Click here to read the full press release.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Appointment of Dr. Kelmendi, Assistant Professor of Psychiatry at Yale University and co-founder of the Yale Psychedelic Science Group, brings another experienced medical professional to Lobe’s advisory team.

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the appointment of Benjamin Kelmendi, MD, Assistant Professor of Psychiatry at Yale University School of Medicine, to its Scientific Advisory Board.

Keep reading... Show less

Ayurcann Holdings Corp. ( CSE: AYUR ) (the “ Company ” or ” Ayurcann “), a Canadian extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, is pleased to unveil further details of its Phase 2 expansion plans.

Ayurcann has commenced trading on the Canadian Securities Exchange (” CSE “) on April 8, 2021 and subsequently announced a private placement of up to $500,000 (” Financing “), as per the Company’s press release dated April 12, 2021. The proceeds of the Financing are intended to be used to further pursue Phase 2 of the expansion of the production capacity of the Company’s Pickering facility.

Keep reading... Show less

New findings suggest the COVID-19 pandemic, combined with expanded state legalization, has attracted new consumers to the category and accelerated cannabis acceptance and adoption.

  • YouGov study indicates the number of current cannabis consumers has increased 56% within just two years compared to the 16% of Americans who reported current consumption in 2018.
  • 23% of current consumers say they tried cannabis for the first time within the past year.
  • More than half of cannabis consumers say they will purchase or try a new product or format this 420, indicating that the holiday is becoming increasingly focused on exploration and trial.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or the “Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, released the results of a survey today showing one in four Americans currently consume cannabis, reporting they’ve tried some form of cannabis within the past twelve months. That’s a significant increase since 2018* when just 16% of U.S. adults reported current consumption, representing a 56% increase in just two years. What’s more, 23% of current cannabis consumers say they tried cannabis for the first time over the past year, suggesting the COVID-19 pandemic, combined with expanded state legalization, has rapidly accelerated cannabis acceptance and adoption in America.

Keep reading... Show less

Acquires Three Operating Dispensaries in Northeast Pennsylvania

Purchase price represents a mid-single digit multiple of KCR’s expected 2021 EBITDA

Keep reading... Show less